PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report)'s stock had its "buy" rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $5.00 price target on the stock. HC Wainwright's price objective would suggest a potential upside of 303.23% from the stock's current price.
PMV Pharmaceuticals Price Performance
Shares of NASDAQ PMVP traded down $0.03 during mid-day trading on Thursday, hitting $1.24. The company had a trading volume of 223,423 shares, compared to its average volume of 285,723. PMV Pharmaceuticals has a 12 month low of $1.20 and a 12 month high of $2.26. The firm has a market cap of $64.40 million, a P/E ratio of -1.24 and a beta of 1.45. The business's 50-day simple moving average is $1.36 and its 200-day simple moving average is $1.49.
PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.08). As a group, sell-side analysts predict that PMV Pharmaceuticals will post -1.06 EPS for the current year.
Institutional Investors Weigh In On PMV Pharmaceuticals
A number of institutional investors have recently bought and sold shares of PMVP. JPMorgan Chase & Co. lifted its holdings in shares of PMV Pharmaceuticals by 2,282.8% during the 4th quarter. JPMorgan Chase & Co. now owns 24,591 shares of the company's stock worth $37,000 after acquiring an additional 23,559 shares during the period. Virtu Financial LLC bought a new stake in PMV Pharmaceuticals in the third quarter valued at about $42,000. Velan Capital Investment Management LP acquired a new position in PMV Pharmaceuticals in the fourth quarter worth about $53,000. Squarepoint Ops LLC lifted its stake in PMV Pharmaceuticals by 68.7% during the fourth quarter. Squarepoint Ops LLC now owns 73,015 shares of the company's stock worth $110,000 after purchasing an additional 29,722 shares during the period. Finally, Northern Trust Corp boosted its holdings in PMV Pharmaceuticals by 23.2% during the fourth quarter. Northern Trust Corp now owns 107,340 shares of the company's stock valued at $162,000 after purchasing an additional 20,190 shares in the last quarter. Institutional investors and hedge funds own 90.20% of the company's stock.
About PMV Pharmaceuticals
(
Get Free Report)
PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.
See Also
Before you consider PMV Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PMV Pharmaceuticals wasn't on the list.
While PMV Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
